Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation , 2018 for the quarter ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals Ltd (BSE Scrip: 539680) has submitted a routine compliance certificate to BSE for the quarter ended December 31, 2025. The certificate, issued by its Registrar and Share Transfer Agent KFIN Technologies Limited, confirms that details of shares dematerialized and rematerialized during the quarter have been furnished to both CDSL and NSDL as required under SEBI regulations. The filing covers standard procedural reporting with no mention of any new share issuance, conversion, or corporate action. Managing Director Bharat Sharma signed the submission on January 13, 2026. There are no financial figures, deal values, or business developments disclosed in this filing.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. It simply confirms that the company is meeting its periodic reporting obligations regarding share movements between physical and demat forms.